Why the study?
EPA and DHA improve metabolic syndrome parameters, but whether these improvements are related to ceramide is unknown.
Do EPA and DHA improve ceramide lipotoxicity and metabolic syndrome parameters?
Do EPA and DHA improve ceramide lipotoxicity and metabolic syndrome parameters?
Preclinical evidence suggests EPA and DHA may attenuate ceramide lipotoxicity and insulin resistance in metabolic syndrome, highlighting a potential mechanism for their metabolic benefits that requires further human study.
Answers are grounded in this paper and cite their sources.
No immediate change to EPA/DHA recommendations in metabolic syndrome; leaves open human translation of preclinical ceramide effects.
The metabolic syndrome (MetS) is a cluster of cardiovascular risk factors including obesity, insulin resistance (IR) and dyslipidaemia. Consumption of a high-fat diet (HFD) enriched in SFA leads to the accumulation of ceramide (Cer), the central molecule in sphingolipid metabolism. Elevations in plasma and tissue Cer are found in obese individuals, and there is evidence to suggest that Cer lipotoxicity contributes to the MetS. EPA and DHA have shown to improve MetS parameters including IR, inflammation and hypertriacylglycerolaemia; however, whether these improvements are related to Cer is currently unknown. This review examines the potential of EPA and DHA to improve Cer lipotoxicity and MetS parameters including IR, inflammation and dyslipidaemia in vitro and in vivo. Current evidence from cell culture and animal studies indicates that EPA and DHA attenuate palmitate- or HFD-induced Cer lipotoxicity and IR, whereas evidence in humans is greatly lacking. Overall, there is intriguing potential for EPA and DHA to improve Cer lipotoxicity and related MetS parameters, but more research is warranted.
No takes yet. Share an insight, caveat, or question.
Walchuk et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: